"On Wednesday the FDA approved Jakafi as a treatment for myelofibrosis. A pill taken twice a day, it's the first drug approved to treat the condition. The disease is currently treated with chemotherapy or bone marrow transplant, and some patients are not eligible for the procedures.
THE BIG PICTURE: Jakafi is Incyte's first approved drug. The company is also testing it as a treatment for pancreatic cancer, solid tumors and blood cancers, and two other blood disorders. Incyte is also studying other treatments for cancers and inflammatory diseases, which are in early- and mid-stage testing.
THE ANALYSIS: JMP Securities analyst Liisa Bayko said the price of Jakafi is higher than she had expected, a good sign for revenue growth, but not too high to risk disapproval from insurers.
Incyte announced a year of treatment will cost $84,000. Bayko estimated the cost after rebates will be $68,000. She said sales of Jakafi will be around $65 million in revenue in 2012, and she said peak sales will reach about $1 billion in 2016.
Bayko rates Incyte shares at "Market Outperform," and she raised her price target on the stock to $27 per share from $23."
Bayko sounds much more credible by giving reasons and evidence for her conclusions. Just opposite of GSucks who are "neutral" ?!?! with a target price of $19 ?!?! apparently ~50% upside is not good enough for a GSucks "buy" rating